<DOC>
	<DOCNO>NCT00004189</DOCNO>
	<brief_summary>Phase I trial study effectiveness rebeccamycin analog cisplatin without filgrastim treat patient advanced cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy .</brief_summary>
	<brief_title>Rebeccamycin Analog Cisplatin With Without Filgrastim Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dos rebeccamycin analogue cisplatin without filgrastim ( G-CSF ) patient advanced malignancy . II . Determine qualitative quantitative toxicity regimens patient . III . Determine pharmacokinetics rebeccamycin analogue affect cisplatin sequence dependent pharmacokinetic effect . IV . Assess antitumor effect regimen patient . OUTLINE : This dose-escalation , multicenter study rebeccamycin analogue cisplatin . Part I ( previously untreated minimally pretreated patient ) : The first patient cohort receive cisplatin IV 1 hour follow 2 hour later rebeccamycin analogue IV 1 hour day 1 . The second patient cohort receive drug reverse order . The drug sequence additional patient within cohort alternate reference precede patient . During subsequent course , study drug administer patient reverse order compare prior course . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . Dose escalation initially perform without filgrastim ( G-CSF ) . Cohorts 4-6 patient receive escalate dos rebeccamycin analogue cisplatin maximum tolerate dose ( MTD ) drug determine . The MTD define high dose less 2 6 patient experience dose limit toxicity ( DLT ) . If 2 first 6 patient experience DLT , dose escalation proceeds combination G-CSF treatment . Patients receive G-CSF subcutaneously daily begin day 2 continue blood count recover 2 day approximately day 15 . Cohorts 4-6 patient receive escalate dos rebeccamycin analogue cisplatin . The MTD define . Part II ( heavily pretreated patient ) : Heavily pretreated patient receive rebeccamycin analogue cisplatin start 2 dose level precede MTD part I . Patients follow least 30 day .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven advanced malignancy refractory prior therapy unlikely benefit standard therapy ( e.g. , chemotherapy , radiotherapy , surgery ) Part I : Previously untreated OR minimally pretreated Ineligible part I consider heavily pretreated : Prior radiotherapy wide port involve pelvis least 25 % bone marrow Greater 6 course prior combination chemotherapy include alkylating agent Prior nitrosoureas mitomycin Widespread bone metastases bone marrow involvement bone marrow biopsy ( positive bilateral bone marrow biopsy lymphoma patient ) Part II : Heavily pretreated defined Measurable evaluable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count great 1,500/mm^3 Hemoglobin great 9 mg/dL Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 1.5 mg/dL Renal : Creatinine le 1.5 mg/dL Cardiovascular : No uncontrolled hypertension No angina pectoris No clinically significant , multifocal , uncontrolled cardiac dysrhythmias Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active serious infection No clinically severe peripheral neuropathy ( grade 1 worse ) No nonmalignant medical condition would preclude compliance increase risk participation study No hypersensitivity E. coli derive drug preparation PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent colony stimulate factor prophylactic purpose Chemotherapy : At least 3 week since prior chemotherapy ( 6 week since prior nitrosoureas mitomycin ) recover Endocrine therapy : No chronic oral corticosteroid No concurrent corticosteroid except prophylactic antiemetic Radiotherapy : At least 3 week since prior radiotherapy recover Other : At least 1 month since prior investigational agent No prophylactic oral IV antibiotic neutropenia unless fever present No concurrent anticancer treatment investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>